MedTrace Logo

A Study of Probiotics in IBS Subjects

NCT03482765 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 336

Last updated 2019-07-05

No results posted yet for this study

Summary

For the current study, the primary outcome is to evaluate the effect of IP on abdominal pain.

The secondary outcome is to assess the effect of IP on IBS-Symptom Severity, IBS-related quality of life, stool form and consistency and on mental status.

Thus providing an effective objective in improving the gut health and symptomatic relief in IBS patients.

Conditions

  • IBS

Interventions

DIETARY_SUPPLEMENT

Probiotic 1

The product under investigation is a unique probiotic.

DIETARY_SUPPLEMENT

Probiotic 2

The product under investigation is a unique probiotic.

OTHER

Placebo

Microcrystalline Cellulose

Sponsors & Collaborators

  • Vedic Lifesciences Pvt. Ltd.

    lead INDUSTRY

Principal Investigators

  • Shalini Srivastava, M.D. · Vedic Lifesciences

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-30
Primary Completion
2019-03-14
Completion
2019-06-30

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03482765 on ClinicalTrials.gov